STAT+: Amid acquisition speculation, Cytokinetics CEO stresses company can launch heart drug on its own
As Cytokinetics faces pressure to sell itself to a large pharma company following positive late-stage results of its heart drug, CEO Robert Blum maintains that the biotech can launch the treatment — what would be its first approved medication — on its own. …